Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Desager, Jean Pierre ^a   Horsmans, Y ^a   Vandenplas, C ^a   Harvengt, C ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Ciprofibrate; Fenofibrate HE; Hepatic lipase (HL); Lipoprotein lipase (LPL); Normolipidaemic

Indexed keywords

CIPROFIBRATE; FENOFIBRATE; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029737127     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05859-5     Document Type: Conference Paper

References (26)

1. Franceschini G, Paoletti R. Drugs controlling triglyceride metabolism. Med Res Rev 1993;13:125.
2. Harvengt C, Heller F, Desager JP. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 1980;7:73.
3. Fievet C, Douste-Blazy P, Drouin P, et al. Effects of fenofibrate on apolipoprotein B-containing particles in patients with hyperlipoproteinemia. Curr Ther Res 1990;47:353.
4. Orö L, Carlson LA, Olsson A, Poole PH. Long term efficacy and safety of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res 1992;51:750.
5. Betteridge DJ. Ciprofibrate - a profile. Postgrad Med J 1993;69(Suppl 1):S42.
6. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69(Suppl 1):S34.
7. Santamarina-Fojo S, Brewer HB Jr. Lipoprotein lipase: structure, function and mechanism of action. Int J Clin Lab Res 1994;24:143.
8. Gaw A, Packard CJ, Caslake MJ, et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994;108:137.
9. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91.
10. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295.
11. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arteriosclerosis Thromb 1993;13:702.
12. Heller F, Harvengt C. Effects of clofibrate, benzafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983;25:57.
13. Kornitzer M, Dramaix M, Vandenbroek MD, Everaert L, Gerlinger C. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6 month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis 1994;110(Suppl):S49.
14. Nilsson-Ehle P, Ekman R. Rapid, simple and specific assays for lipoprotein lipase and hepatic lipase. Artery 1977;3:194.
15. Dobiasova M. Lecithin: cholesterol acyltransferase and the regulation of endogenous cholesterol transport. Adv Lipid Res 1983;20:107.
16. Labeur C, Michiels G, Bury J, Usher DC, Rosseneu M. Lipoprotein Lp(a) quantified by an enzyme-linked immunosorbent assay with monoclonal antibodies. Clin Chem 1989;35:1380.
17. Sheiner LB. ELSFIT (version 3.0) A program for the extended least squares fit to individual pharmacokinetic data. San Francisco: University of California, 1983.
18. Miller M, Bachorik PS, McCrindle BW. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomised, double-blind, placebo-controlled, crossover study. Am J Med 1993;94:7.
19. 3 in normolipidaemic subjects. Eur J Clin Invest 1993;23:122.
20. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmac Ther 1994;61:289.
21. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by Apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Arteriosclerosis Thromb 1994;14:707.
22. Horsmans Y, Desager JP, Harvengt C. Effects of gemfibrozil on the activities of plasma lipolytic enzymes in normolipidemic subjects. Clin Chim Acta 1993;218:223.
23. Heller FR, Desager JP, Harvengt C. Plasma lipid concentrations and lecithin: cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 1981;30:67.
24. Davison C, Benziger D, Fritz A, Edelson J. Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl) phenoxy]-2-methylpropanoic acid, WIN 35833, in rats, monkeys and men. Drug Metab Disp 1975;3:520.
25. Desager JP, Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol 1978;16:570.
26. Guichard JP, Levy-Prades Sauron R. A comparison of the bioavailability of standard or micronized formulations of fenofibrate. Curr Ther Res 1993;54:610.